Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Opioids

FDA to hold public meeting on abuse-deterrent opioid formulations

Scott Gottlieb, Commissioner, Food and Drug Administration (FDA)

Source: Rex / Shutterstock

Scott Gottlieb, commissioner of the FDA, says the agency is committed to looking at all facets of the complex issue of abuse.

The US Food and Drug Administration (FDA) is holding a public meeting in July to discuss the role of opioid formulations that are intended to prevent abuse and addiction.

The agency’s commissioner Scott Gottlieb said in a press statement that while such products “may hold promise” in deterring abuse, there is currently a lack of real-world evidence as to their impact.

The public workshop will focus on how to improve analysis of existing data and how to optimise future studies. It will also include discussion of ways to improve national surveillance and research capabilities in the area.

“The FDA is committed to looking at all facets of this complex issue and collaborating on various approaches, as there are no simple answers to reverse this epidemic,” said Gottlieb.

Abuse-deterrent technologies are relatively recent and include a number of strategies. These include adding physical barriers to prevent the grinding and crushing of tablets, or the inclusion of gelling agents that resist solvent extraction. Another example is the incorporation of an opioid antagonist such as nalaxone that becomes activated when manipulated and counteracts the euphoria associated with the drug.

The FDA’s position is that it encourages the development of such formulations and it has approved labelling for a number of non-generic opioid medications, allowing them to describe abuse-deterrent properties.

Last month, the FDA announced new policy steps, which it said were part of a more forceful approach to tackling the country’s opioid addiction epidemic. The steps included the formation of a steering committee focused on preventing new cases of addiction.

Earlier this week, the FDA also announced it had requested the withdrawal of an abuse-deterring opioid formulation called Opana ER. They said that a reformulation of the drug with a coating to prevent abuse from snorting had driven abusers to inject the drug instead, resulting in an outbreak of HIV and hepatitis C virus.

The workshop will be held in Maryland on 10 and 11 July 2017.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2017.20203009

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Scott Gottlieb, Commissioner, Food and Drug Administration (FDA)

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.